Characterization of different osteosarcoma phenotypes by PET imaging in preclinical animal models

C Campanile, MJE Arlt, SD Krämer… - Journal of Nuclear …, 2013 - Soc Nuclear Med
The aim of this study was to characterize the different phenotypes of osteosarcoma by PET,
comparing the uptake of 3 tracers (18F-FDG, 18F-fluoromisonidazole [18F-FMISO], and 18F …

PET imaging of osteosarcoma

W Brenner, KH Bohuslavizki… - Journal of Nuclear …, 2003 - Soc Nuclear Med
During the past decade the clinical value of PET imaging has been investigated for many
different tumors. As knowledge of the advantages and limitations of this modality increased …

18F and 18FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation

C Arvanitis, PK Bendapudi, JR Tseng… - Cancer biology & …, 2008 - Taylor & Francis
Osteosarcoma is one of the most common pediatric cancers. Accurate imaging of
osteosarcoma is important for proper clinical staging of the disease and monitoring of the …

Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT

WK Hsu, MS Virk, BT Feeley, DB Stout… - Journal of Nuclear …, 2008 - Soc Nuclear Med
The combination of small-animal PET/CT scans and conventional imaging methods may
enhance the evaluation of in vivo biologic interactions of murine models in the study of …

[HTML][HTML] Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [18F]FDG and sodium [18F]fluoride PET

M Collantes, N Martínez-Vélez, M Zalacain, L Marrodán… - BMC cancer, 2018 - Springer
Background Osteosarcoma is the most common malignant bone tumor in children and
young adults that produces aberrant osteoid. The aim of this study was to assess the utility of …

Biodistribution, pharmacokinetics and PET imaging of [18F] FMISO,[18F] FDG and [18F] FAc in a sarcoma-and inflammation-bearing mouse model

RS Liu, TK Chou, CH Chang, CY Wu… - Nuclear medicine and …, 2009 - Elsevier
2-Deoxy-2-[18F] fluoro-d-glucose ([18F] FDG),[18F] fluoroacetate ([18F] FAc) and [18F]
fluoromisonidazole ([18F] FMISO) were all considered to be positron emission tomography …

Clinical overview of the current state and future applications of positron emission tomography in bone and soft tissue sarcoma

PH Chen, DA Mankoff, RA Sebro - Clinical and Translational Imaging, 2017 - Springer
Purpose Positron emission tomography (PET) provides a noninvasive, functional
assessment providing incremental diagnostic value over magnetic resonance imaging (MRI) …

18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model

A Dutour, AV Decouvelaere, J Monteil… - Journal of Nuclear …, 2009 - Soc Nuclear Med
Assessment of osteosarcoma response to neoadjuvant chemotherapy is performed by
histopathologic analysis after surgical resection of the primary tumor. The purpose of this …

Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model

Z Cheng, R Wei, C Wu, H Qing, X Jiang… - Nuclear Medicine …, 2015 - journals.lww.com
Objective 18 F-Fluorodeoxyglucose (18 F-FDG), 18 F-fluoro-3′-deoxy-3′-L-
fluorothymidine (18 F-FLT), 18 F-fluoromisonidazole (18 F-FMISO), and 18 F-AlF-NOTA …

The possible role of PET imaging toward individualized management of bone and soft tissue malignancies

E Tabacchi, S Fanti, C Nanni - PET clinics, 2016 - pet.theclinics.com
Bone and soft tissue sarcomas represent a heterogeneous group of malignancies including
more than 50 histologic subtypes. 1, 2 Soft tissue sarcomas (mesodermal origin) represent …